title: Combination of budesonide and aminophylline diminished acute lung injury in animal model of meconium aspiration syndrome.
abstract: Combination of low-dose budesonide and low-dose aminophylline may improve lung function in reduced adverse effects compared with high-dose monotherapy. Adult rabbits intratracheally received 4 ml/kg of saline or meconium (25 mg/ml). Meconium-injured rabbits were treated at 0.5 and 2.5 h after meconium instillation by intravenous aminophylline (1.0 mg/kg), by intratracheal budesonide (0.125 mg/kg) followed by intravenous aminophylline (1.0 mg/kg), or were untreated. Although aminophylline improved some respiratory parameters, budesonide+aminophylline more effectively reduced intrapulmonary shunts and improved gas exchange, without significant cardiovascular effects. Combined treatment reduced lung edema and number of lung neutrophils to a higher extent than aminophylline alone. Both treatments reduced lung peroxidation and in vitro airway reactivity to histamine, with a better effect after aminophylline alone. Combination of budesonide and aminophylline enhanced respiratory parameters more effectively, having fewer side effects than aminophylline alone. However, no additive effect of budesonide was observed on lung peroxidation and in vitro airway reactivity.
authors.affiliation: Department of Physiology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia. mokra@jfmed.uniba.sk
authors.forename: D
authors.initials: D
authors.lastname: Mokra
authors.forename: A
authors.initials: A
authors.lastname: Drgova
authors.forename: J
authors.initials: J
authors.lastname: Mokry
authors.forename: J
authors.initials: J
authors.lastname: Bulikova
authors.forename: R
authors.initials: R
authors.lastname: Pullmann
authors.forename: P
authors.initials: P
authors.lastname: Durdik
authors.forename: M
authors.initials: M
authors.lastname: Petraskova
authors.forename: A
authors.initials: A
authors.lastname: Calkovska
mesh_terms: D000628:Aminophylline / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000831:Animals, Newborn; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007118:Immunoassay; D007231:Infant, Newborn; D007275:Injections, Intravenous; D007958:Leukocyte Count; D015227:Lipid Peroxidation / Q000187:drug effects; D008171:Lung Diseases / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D008471:Meconium Aspiration Syndrome / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D020556:Neutrophil Infiltration / Q000187:drug effects; D010100:Oxygen / Q000097:blood; D011817:Rabbits; D012129:Respiratory Function Tests; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014132:Trachea / Q000503:physiopathology
chemical_list: D001993:Bronchodilator Agents; D017392:Thiobarbituric Acid Reactive Substances; D000628:Aminophylline; D019819:Budesonide; D010100:Oxygen